Biotech & Longevity · Friday, 9 October 2026
Argenx's best-selling drug Vyvgart fails in Sjogren's disease, wiping 15% off its shares, while a celiac drug it bought passes a mid-stage trial
An outside board stopped argenx's final trial of Vyvgart in Sjogren's disease a year early, and the shares fell 15% the same day its celiac drug FB102 passed a mid-stage test. Also today, Viatris agreed to buy the painkiller maker Pacira for $1.65 billion, Robert F. Kennedy Jr. opened an NIH clinic for vaccine injuries, and the first human test of cell reprogramming reported early safety results.
15%
the fall in argenx's share price on Thursday
the company is still worth about $50 billion, more than Biogen, which has a dozen approved drugs
$1.5bn
Vyvgart sales in one quarter, April to June
analysts expect $11 billion to $17 billion a year at its peak, even without Sjogren's
126
adults with celiac disease given gluten in the FB102 trial
their gut lining was measured at Day 78 and compared with people on a dummy drug
9 to 1
women to men among people who get Sjogren's
the disease is chronic and slowly gets worse, and is often misdiagnosed for years
The lead story — what happened
-
Argenx, a Dutch drug company worth about $50 billion, said on Thursday it is stopping a final-stage trial of its drug Vyvgart in Sjogren's disease.
[1] [3] -
Sjogren's is a disease in which the immune system attacks the glands that make tears and saliva. It often brings tiredness, dry eyes and pain in the mouth and joints.
[1] [3] -
An outside board of experts, who can see the results while a trial is still running, looked at them partway through. It found the trial could not meet its main goal and advised stopping.
[3] -
Results had not been expected until the second half of 2027.
[1] Argenx said Vyvgart caused no new safety problems in the trial.[3] -
Vyvgart blocks a receptor called FcRn, and that lowers the level of IgG antibodies in the blood. In Sjogren's and similar diseases, some of those antibodies attack the body's own tissue.
[3] -
Argenx shares fell 15% on Thursday.
[1] Vyvgart and an under-the-skin version brought in $1.5 billion in the second quarter alone.[1] -
Several analysts had left Sjogren's out of their sales forecasts because the trial was risky. A win could have added up to $1.4 billion a year in sales at its peak.
[1] -
It is not Vyvgart's first miss. Trials in a bleeding disorder and a skin disease failed in 2023, and argenx dropped thyroid eye disease in 2025.
[1] -
No approved medicine changes the course of Sjogren's. Novartis and Amgen have each reported a successful final-stage trial of their own drugs.
[1] -
The same morning, argenx said its newer drug FB102 passed a mid-stage trial in celiac disease, in which eating gluten damages the lining of the gut.
[2] [1] -
The trial gave 126 adults with celiac disease gluten on purpose. Those on FB102 had less damage to the tiny folds of their gut lining at Day 78 than those on a dummy drug.
[2] -
Argenx has not yet said how big the protection was, only that it was unlikely to be chance. It bought FB102 this year by taking over Forte Biosciences for $2.2 billion, and plans a final-stage trial.
[2]
Who is involved
-
Argenx
a Dutch drug company that makes Vyvgart, a treatment for immune diseases; it stopped the Sjogren's trial
-
The independent data monitoring committee
outside experts who can see a trial's results while it runs; they advised stopping it
-
Luc Truyen
argenx's chief medical officer; he said patients are still waiting for treatments that change the disease
-
Novartis and Amgen
two large drugmakers; each has reported a successful final-stage trial in Sjogren's
-
Teva
a drugmaker testing a rival celiac drug, TEV-408, which needs another mid-stage trial first
How it unfolded
-
2023 Vyvgart fails trials in a bleeding disorder and a skin disease
[1] -
2025 argenx drops Vyvgart for thyroid eye disease
[1] -
July 2026 argenx agrees to buy Forte Biosciences, and FB102, for $2.2 billion
[2] -
8 Oct 2026 the Sjogren's trial is stopped and the celiac trial passes; shares fall 15%
[1] [2] [3] -
2031 the earliest year TD Cowen analysts expect FB102 could reach patients
[2]
Where this points
Watch for the full Sjogren's data argenx has promised to analyse and share, and for the size of FB102's effect, which it has not yet published.
What is pushing on the whole day
The bar and the word are our reading of how hard each one is pushing today. The arrow is where it is heading. The evidence is in the stories below.
Viatris, a maker of generic and branded medicines, agreed to pay $1.65 billion for Pacira and its two pain drugs already on sale.
Robert F. Kennedy Jr., the US health secretary, opened a clinic at the National Institutes of Health to study injuries blamed on vaccines.
The US Labor Department sent subpoenas to nine universities over visas for foreign researchers.
The European Union's health committee met about a possible plague death in Siberia and decided nothing without Russia's test results.
The rest of the day
22 more stories on this beat.
Each with its own sources. None of these is a link to the story above.
-
02
Viatris buys Pacira for $1.65 billion
Viatris, a maker of generic and branded medicines, agreed on Thursday to buy Pacira BioSciences for $1.65 billion in cash.
[4] [5] [6] It will pay $36.50 a share, 45% more than Pacira's price the day before.[4] Pacira sells Exparel, for pain after surgery, and Zilretta, for knee pain from osteoarthritis.[4] Both are new forms of old painkillers that are not opioids, and together they sold $692 million in 2025.[4] The deal should close by the end of 2026.[4] Why it matters — Cheaper copies of Exparel can start selling in early 2030 under patent deals Pacira made last year, and Zilretta's patents end in 2031.
[4] Viatris says it knows how to keep a drug selling after copies arrive.[4] -
03
Roche's weekly weight shot tested in diabetes
Zealand Pharma, a Danish company, and its partner Roche reported a mid-stage trial of petrelintide in 220 people with obesity and type 2 diabetes.
[7] Petrelintide is a weekly injection that copies amylin, a natural hormone.[7] The pancreas releases amylin along with insulin, and it helps people feel full. People lost up to 9.2% of their weight in 28 weeks, against 2% on a dummy shot.[7] But HbA1c, a blood test of average sugar over months, fell by only 0.65%, while rival drugs have cut it by 1.3% to 2.1%.[7] Petrelintide0.65%Rival drugs, lowest1.3%Rival drugs, highest2.1%How far each drug lowered HbA1c, a measure of average blood sugar, in separate trials. These come from different trials, so the comparison is rough. Why it matters — Stomach side effects were about as common as on the dummy shot, so analysts at William Blair now expect it to be used mainly to keep weight off.
[7] Roche has started three final-stage trials, one of them in 600 people with diabetes.[7] -
04
Kennedy opens an NIH clinic for vaccine injuries
Robert F. Kennedy Jr., the US health secretary, opened a clinic at the National Institutes of Health, the US medical research agency, to study injuries blamed on vaccines.
[8] He visited on Monday, and thousands of NIH staff were told to work from home that day.[8] An internal memo seen by NPR says the NIH will follow vaccinated people for possible complications.[8] Kennedy also plans a billing code that pays doctors for reporting serious vaccine side effects.[9] Why it matters — Vaccine experts say systems already watch very large numbers of people for side effects.
[8] Some fear the clinic is meant to back Kennedy's long-debunked claim that vaccines cause autism, while measles cases rise in the US.[8] [9] -
05
First human test of cell rejuvenation
Life Biosciences released the first safety results from a human trial of cellular reprogramming, a method meant to return old cells to a younger state.
[10] Three people with glaucoma, an eye disease that can cause blindness, got an eye injection plus eight weeks of daily antibiotics that switch the treatment on.[10] None reported major side effects, and two of the three improved on a standard eye exam.[10] The method had made mice and monkeys younger in tests, but had never been tried in people.[10] 2 of 3
patients who improved on a standard eye exam
Each figure is one of the three people treated so far. Two improved on an eye exam; three is far too few to know why. Why it matters — James Tsai, a glaucoma specialist at Mount Sinai who was not involved, called it exciting but very preliminary.
[10] New Limit, which raised $435 million, plans its own human trial in 2027.[10] -
06
FDA's abortion pill review runs into 2027
The FDA said its safety review of mifepristone, the main abortion pill in the US, will continue into next year.
[11] It expects to finish a safety study by mid-December and report no later than March 2027, then decide on any new limits.[11] The update came in a court filing ordered in a case brought by Louisiana.[11] Mifepristone was approved in 2000, and the FDA has repeatedly found it safe and effective.[11] Why it matters — Since 2021, doctors may prescribe it online and send it by post, which has weakened state abortion bans.
[11] That rule is the one abortion opponents most want changed, and they criticised the new timeline.[11] -
07
Drugmakers sue over a Medicare price test
PhRMA, the trade group for brand-name drugmakers in the US, sued the Trump administration over GLOBE, a Medicare pilot.
[12] GLOBE ties what Medicare pays for some drugs to the prices other rich countries pay.[12] It covers Part B, the part of Medicare that pays for drugs given in doctors' offices. PhRMA says the pilot goes beyond what the law allows Medicare to do.[12] The Trump administration had already exempted all but a handful of companies, in return for voluntary price deals.[12] Why it matters — The pilot is not expected to change much, so the fight is about the example it would set.
[12] PhRMA says voluntary deals are acceptable but a compulsory one is not.[12] -
08
Plan to allow some restricted peptides
The Trump administration is drafting plans to allow the temporary sale of some peptides that are now restricted, the Washington Post reported.
[12] These are sold as new treatments and wellness products.[12] Peptides are short chains of the building blocks that make up proteins. The plan would let some compounding pharmacies, which mix medicines to order, sell them while federal rules are written.[12] Why it matters — The plan has not been announced and could still change.
[12] If it goes ahead, pharmacies could sell these products before their claims are fully tested.[12] -
09
Ono pays $80 million for Biohaven drugs in Asia
Ono Pharmaceutical of Japan will pay Biohaven $80 million up front for rights to three experimental drugs in Japan, South Korea, Taiwan and Southeast Asia.
[13] Biohaven can also earn a $20 million payment and 20% of profits there.[13] The lead drug, BHV-1300, is in a final-stage trial for Graves' disease, in which antibodies push the thyroid to overwork.[13] It is a degrader: it clears some kinds of antibody out of the blood.[13] Why it matters — Biohaven cut back its research in March and kept these drugs as one of three areas.
[13] Ono, which helped develop the cancer drug Opdivo, wants more medicines for immune diseases.[13] -
10
EU presses Russia over a possible plague death
The European Commission said for the third time this week that Russia must share details of a suspected plague case in Siberia.
[14] A 28-year-old worker at a plague research institute in Irkutsk died last week.[15] The EU's health security committee met with the WHO on Wednesday and took no decisions, because it lacked reliable information.[14] Russia says she died of pneumonia of unknown cause, and that it has checked 90% of her contacts and found no infections.[15] Why it matters — The WHO asked Russia for details on 3 October and got an answer on 6 October.
[15] Until the test results are shared, nobody outside Russia can judge the risk.[15] [14] -
11
Kenya's second suspected Ebola case is negative
Early lab tests on a 20-year-old man in Wajir, Kenya, who was suspected of having Ebola, came back negative, the county governor said on Thursday.
[16] He had travelled from Congo through Uganda, the same route as a Kenyan man who died of Ebola in Nairobi this week.[16] Kenya is the fourth country with a case linked to Congo's outbreak, the second-largest on record.[16] It has killed at least 4,205 of more than 8,700 people reported ill.[16] Why it matters — The result eased fears of a second case in Kenya.
[16] The outbreak was declared in Congo in May and has since reached three other countries.[16] -
12
US investigates nine universities over researcher visas
The US Labor Department is investigating nine universities, including Harvard, MIT and Stanford, over J-1 visas, the main visa for foreign researchers just after their PhD.
[17] Vice President JD Vance said the schools use the visas to bring in cheap labour.[17] He said they fill 61% of grant-funded research jobs with J-1 holders, against 38% nationally, and his office did not immediately say where the figures came from.[17] MIT and Harvard confirmed they had received subpoenas.[17] Why it matters — Nearly 60% of US postdoctoral researchers in science, engineering and health hold temporary visas, government science data show.
[17] The same week, the Trump administration proposed a $70,000 fee on a work programme used by foreign students.[17] -
13
An epilepsy drug protects arthritic joints in animals
Yale researchers reported that lacosamide, an approved epilepsy drug, eased pain and protected cartilage in early tests for osteoarthritis, before any human trial.
[18] The drug blocks Nav1.7, a channel that carries pain signals and, in arthritic joints, also pushes cartilage cells to break down.[18] Held in a gel injected into the knee, one dose every four weeks protected cartilage better than a daily pill.[18] The study was published in Bioactive Materials.[18] Why it matters — No approved medicine stops both the pain and the cartilage loss of osteoarthritis.
[18] Because lacosamide is already approved, human trials could start sooner, but it has not yet been tested in people with osteoarthritis.[18] -
14
Cells' family trees traced in mouse embryos
Two teams published maps of how every cell in a mouse embryo descends from the fertilised egg, in the journals Science and Cell.
[19] One used DNA Typewriter, which writes a record of each cell division into the cell's own DNA, in order.[19] Of 100 edited eggs, ten embryos were examined, and one held a record clear enough to trace nearly every cell to one of the first two.[19] The other team traced 1.4 million cells from 16 embryos.[19] Why it matters — Blood and eye cells settled their fate early and outer skin cells late, so cells do not choose their jobs all at once.
[19] The researchers say such records could help study birth defects and cancer.[19] -
15
Big dogs and male dogs age faster in their DNA
A study of 894 pet dogs in the Dog Aging Project found that large dogs and male dogs age faster at the molecular level, in a study published in Science.
[20] Researchers at Arizona State University read chemical tags on the dogs' DNA, which change with age and work as a clock.[20] Ageing on this clock was fastest early in a dog's life.[20] Small breeds can live nearly twice as long as large ones.[20] Why it matters — Pet dogs share human homes, food and medical care, so researchers use them to study how genes and surroundings shape ageing in people.
[20] -
16
US funds cell treatments that need no fridge
ARPA-H, a US health research agency, has named three teams in BoSS, a programme to store and ship cell-based medicines without refrigeration.
[21] It has promised up to $87 million over four years.[21] A team led by Draper and Likarda got up to $7.3 million at first, and one led by UC Davis up to $6 million.[21] Cell treatments are living cells, and today they must be kept cold from factory to patient.[21] Why it matters — The teams aim to cut the cost of storing, moving and delivering these treatments.
[21] One test will check whether stored cancer-fighting immune cells still work once they are woken up.[21] -
17
A week of weight training shrank fat cells in mice
Researchers at Brazil's University of Campinas made mice obese with a high-fat diet, then had half of them climb a staircase carrying weights.
[22] After seven sessions, the trained mice had less fat around their gut and smaller fat cells, though their body weight had not changed.[22] Proteins that break down stored fat had started working again.[22] The study was published in Life Sciences.[22] Why it matters — Fat around the organs is more harmful than fat under the skin, and this suggests exercise starts to change it before the scales move.
[22] It was done in male mice only.[22] -
18
How the Covid virus may harm insulin cells
A study in a Nature journal reports how the virus behind Covid-19 may damage the cells that make insulin.
[23] Two of the virus's proteins grab a hormone called IAPP and make it clump into deposits that disrupt insulin release.[23] In infected macaques, old animals had many deposits and dying insulin cells, while younger adults had few.[23] The work used monkeys, mouse cells and lab tests, not patients.[23] Why it matters — Diabetes cases have risen since the pandemic, and this offers one possible reason, and a reason age matters.
[23] -
19
Stick-on injector delivers a myeloma drug
A French mid-stage trial gave isatuximab, an antibody drug for the blood cancer multiple myeloma, through a small device stuck to the body instead of a drip.
[24] The 74 patients, median age 73, could not have a stem-cell transplant.[24] At eight months, 88% had a very good response, and about 93% had no worsening at 14 months.[24] Only 5% had reactions to the injection.[24] Why it matters — The authors say the stick-on injector is a workable alternative to giving the drug by drip.
[24] The trial was run by the University Hospital of Poitiers, not by a drug company.[24] -
20
First African to lead a world cancer body
Zainab Shinkafi-Bagudu, a Nigerian children's doctor, is president-elect of the Union for International Cancer Control, and the first African to lead it.
[25] It has more than 1,100 member groups in over 170 countries.[25] The WHO's cancer agency counted 20.6 million new cancer cases and 9.8 million deaths in 2024.[25] It expects more than 34 million cases a year by 2050, with most of the extra deaths in poorer countries.[25] New cancer cases, 202420.6 mForecast, 205034 mNew cancer cases in the world each year, in millions, counted for 2024 and forecast for 2050 by the WHO's cancer agency. Why it matters — She wants a global fund for cancer treatment, like the one that pays for HIV, tuberculosis and malaria care.
[25] Only 14% of the 73 million people who need end-of-life pain care each year get it.[25] -
21
UK puts 54 million pounds into future vaccines
The UK government and UK Research and Innovation, its research funder, are putting 54 million pounds into 18 projects against biological threats.
[26] They include mRNA vaccines for farm animals and work on germs that no longer respond to drugs.[26] One in six lab-confirmed bacterial infections tested resistant to antibiotics in 2023, UKRI says.[26] Three government departments pay for it: health, farming and foreign affairs.[26] Why it matters — The programme treats human, animal and plant disease as linked, so outbreaks on farms and in hospitals are studied together.
[26] -
22
Fathers dying in the years after a birth
Northwestern University researchers followed the fathers of all 130,267 babies born in the US state of Georgia in 2017, for five years.
[27] 796 of the fathers died, and 60% of those deaths were from causes judged preventable.[27] They included 143 killings, 142 accidents, 102 suicides and 93 overdoses.[27] Overall, fathers died less often than other men: 120 against 231 per 100,000 at ages 30 to 34.[27] - Natural causes296 · 37%
- Killed by others143 · 18%
- Accidents142 · 18%
- Suicide102 · 13%
- Overdose93 · 12%
- Other20 · 3%
How the 796 fathers who died within five years of a birth in Georgia died. The 20 'other' are the remainder of the total. Why it matters — Deaths of mothers around a birth are reviewed by official committees, and nothing like that exists for fathers.
[27] The study was published in JAMA Pediatrics.[27] -
23
AI breast cancer risk test sold straight to women
Everlywell, a US digital health company, has launched Clairity Breast, which predicts a woman's five-year breast cancer risk from an uploaded mammogram for $249.
[28] It is one of a growing number of AI tools for medical images sold straight to patients.[28] Many such tools have been slow to reach patients through doctors, who are often unsure how useful an early tool is before it has been studied in real use.[28] Why it matters — Selling straight to patients means a woman can get an AI risk score without a doctor ordering it.
[28]
Why a trial gives people the harm its drug should block
To show a drug prevents damage, researchers give everyone in the trial a small, measured dose of what causes it, then compare who was protected.
The twist
To prove a drug blocks a harm, a trial has to make the harm happen. So it gives everyone the same small dose of the cause, one that can be stopped at any time.
How it works
- Celiac damage happens only when gluten is eaten
- People with celiac disease avoid gluten, so their gut has little damage to compare
- So the trial gives everyone a set amount of gluten
- Half also get the drug, half a dummy
- Less gut damage in the drug group shows protection
The same force, elsewhere today
Where this chain is also running, in today's other stories.
-
A week of weight training in mice
The mice were first made obese on a high-fat diet, so the exercise had a known amount of fat to work on.
-
How the Covid virus may harm insulin cells
Macaques were infected with the virus, so researchers could compare the damage in old and younger animals.
Where you've seen this
Car crash tests
Carmakers crash new cars into walls with dummies inside instead of waiting years for real crashes.
Malaria vaccine trials
Volunteers are bitten by infected mosquitoes under close watch and treated at once if they fall ill.
Food allergy tests
Doctors give a child tiny, rising amounts of peanut in a clinic to see whether a reaction comes.
The catch
The harm a trial makes is smaller, shorter and simpler than the real one. Weeks of measured gluten are not years of slips, and a mouse made fat in weeks is not a person who gained weight over decades.
And the whole of it
The 126 adults in this trial ate gluten they normally avoid, so that a drug could be judged for everyone else with celiac disease. In daily life, gluten slips in now and then for years, and no short trial can show whether the drug protects against that. If it is approved, the patients who take it will be the first to find out.
What is really going on
An outside board stopped argenx's Sjogren's trial a year early because it could no longer succeed, and argenx shares still fell 15%, though several analysts had never counted on a win.
Why it works on us — A clinic named for vaccine injuries presents those injuries as a known group of patients before any study has counted how many there are.
Who gains
-
Novartis and Amgen
— Each has reported a successful final-stage Sjogren's trial, and argenx's failure removes a rival drug from that race.
[1] -
Pacira's shareholders
— Viatris is paying $36.50 a share in cash, 45% above the price the day before the deal.
[4] -
Ono Pharmaceutical
— For $80 million up front it gets Asian rights to three drugs, one already in a final-stage trial.
[13] -
Fresenius Kabi and a Hengrui unit
— Their patent deals with Pacira let them sell copies of Exparel from early 2030, whoever owns it.
[4] -
The biggest US drugmakers
— Their deals with the Trump administration keep them free of the new tariffs for now, while smaller firms pay.
[28]
Who pays
-
People with Sjogren's disease
— There is still no approved medicine that changes the course of the disease, and one of the drugs being tested has now failed.
[1] [3] -
Argenx's shareholders
— The shares fell 15% in one day on news analysts had not expected until late 2027.
[1] -
Foreign researchers at the nine universities
— Their universities now face Labor Department subpoenas over the J-1 visas most of them work on.
[17] -
Smaller biotech companies
— They are still paying new US tariffs and say they cannot plan research or launches until the rules are clear.
[28] -
About 200 contacts of the Irkutsk worker
— Russia placed them under medical watch, and several hospitals were reported quarantined.
[15]
What nobody knows yet
Open questions from across today’s stories — ours included.
-
01
Why Vyvgart failed in Sjogren's.
Argenx has shared no numbers from the trial and will only analyse the data after the study is closed and its database locked.
[3] -
02
How much FB102 actually protected the gut.
Argenx has released only a measure of how unlikely the result is to be chance, not the size of the effect.
[2] -
03
What killed the worker at the Irkutsk plague institute.
Russia says pneumonia of unknown cause, while the WHO says it still cannot do a risk assessment without the lab results.
[15] [14] -
04
Whether the two glaucoma patients improved because of the treatment.
Only three people have been treated, and a specialist not involved said the gain could come from better signals in eyes that still had some sight.
[10] -
05
What the new NIH clinic will actually study.
Its plans are known only from an internal memo seen by NPR and from people who spoke without permission; the health department did not comment.
[8] [9] -
06
Where Vance's 61% visa figure comes from.
Neither the US president's office nor Vance's office replied at once when STAT asked, and national data show about 60% of science postdocs already hold temporary visas.
[17] -
07
Whether petrelintide's weak blood sugar result is real.
Blood sugar unusually rose in the dummy group, which narrows the gap after adjusting, and the comparison with rival drugs comes from different trials.
[7] -
08
How long Exparel keeps its sales once copies arrive.
Patent deals allow copies from early 2030, and two other makers are still challenging patents that run to 2044.
[4]
In a French trial, 74 people with the blood cancer myeloma who could not have a transplant got their antibody drug from a small injector stuck to the skin. Eight months in, 88% had a very good response.
Also true today
- Early tests on a 20-year-old man in Kenya, feared to be the country's second Ebola case, came back negative.
- A new celiac drug, FB102, protected the gut lining of 126 adults who were given gluten in a mid-stage trial, its maker said, and it now moves to a final trial.
More from Biotech & Longevity
Across the beats